Search Results - masanori+onda

5 Results Sort By:
Star, Branched, and Graft Polymers in Binders for Inkjet Additive Manufacturing for Personalized Dosage Tablets
THE CHALLENGE A major problem posed by the pharmaceutical industry is giving effective dosages while not giving excessive amounts of a particular drug. An estimated 80% of side effects in humans and animals are a direct result of inaccurate dosing because varying weights in patients. Additive manufacturing has emerged as a very promising method to...
Published: 1/31/2024   |   Inventor(s): Emily Wilts, Timothy Long, Christopher Williams, Da Ma
Keywords(s):  
Category(s): Technology Classifications > Additive Manufacturing, Technology Classifications > Biomedical, Technology Classifications > Chemicals/Materials, Technology Classifications > Pharmacology and Therapeutics
Increased Therapeutic Effectiveness of PE-Based Immunotoxins
Abstract: Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies...
Published: 5/21/2024   |   Inventor(s): Ira Pastan, Masanori Onda, Wenhai Liu
Keywords(s): B-CELL, CHEMOTHERAPY, Human B cell epitopes, Immunogenic epitopes, Immunotoxin, Pseudomonas exotoxin A, T-cell
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents
Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...
Published: 5/21/2024   |   Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho
Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent
Abstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which...
Published: 5/21/2024   |   Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho
Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness
Abstract: Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased...
Published: 5/21/2024   |   Inventor(s): Ira Pastan, Richard Beers, Masanori Onda
Keywords(s): Breast, HEAD, Hematological cancer, Immunotoxin, Ligand-targeted toxin, LUNG, NECK, OVARIAN, Toxin domain
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Cardiology